Oculis Holding AG Ordinary shares (OCS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Oculis Holding AG Ordinary shares, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Oculis Holding AG Ordinary shares (OCS) has returned 33.15% so far this year and 39.73% over the past 12 months.

Based on dividend-adjusted daily data since Mar 2, 2023, OCS's average daily return is +0.16%, while the average monthly return is +3.59%. At this rate, your investment would double in approximately 1.6 years.

Historically, 59% of months were positive and 41% were negative. The best month was Apr 2023 with a return of +49.8%, while the worst month was Mar 2023 at -33.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.

On a daily basis, OCS closed higher 47% of trading days. The best single day was Oct 21, 2024 with a return of +18.1%, while the worst single day was May 8, 2023 at -18.5%.

Oculis Holding AG Ordinary shares has an annualized alpha of 33.07%, beta of 0.63, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since March 03, 2023.

• This stock captured 117.20% of S&P 500 Index gains but only 18.78% of its losses — a favorable profile for investors.
• Beta of 0.63 may look defensive, but with R² of 0.04 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

OCS ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Oculis Holding AG Ordinary shares (OCS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Oculis Holding AG Ordinary shares. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Oculis Holding AG Ordinary shares was 37.53%, occurring on Mar 24, 2023. Recovery took 20 trading sessions.

The current Oculis Holding AG Ordinary shares drawdown is 11.34%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Oculis Holding AG Ordinary shares over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Oculis Holding AG Ordinary shares is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.